Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma.

Yaya ChuGaurav NayyarNang Kham SuJeremy M RosenblumPatrick Soon-ShiongJohn LeeJeffrey T SafritMatthew BarthDean LeeMitchell S Cairo

Published in: Journal for immunotherapy of cancer (2021)

Our results provide the rationale for the development of a clinical trial of N-820 alone or in combination with endogenous or ex vivo expanded NK cells in patients with CD20+ B-NHL failing prior rituximab containing chemoimmunotherapy regimens.

Keyphrases

nk cells
natural killer cells
clinical trial
diffuse large b cell lymphoma
phase ii
open label
double blind
study protocol
chronic lymphocytic leukemia